5% Off
Bevacimab400 mg/16
Healthcare Pharmaceuticals Ltd.
৳76000.00
Add to cart
Generic medicine
Bevacizumab: Brands, Price & Uses in Bangladesh
Bevacizumab is a recombinant humanized monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), used mainly in oncology as part of combination chemotherapy regimens.
About Bevacizumab
Indications of Bevacizumab
Bevacizumab is a recombinant humanized monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), used mainly in oncology as part of combination chemotherapy regimens. Its evidence-based indications, by strength of evidence, are:
FDA-approved / guideline-supported uses (in combination with chemotherapy or other agents, per specific approved regimens)
- Metastatic colorectal cancer - in combination with fluoropyrimidine-based chemotherapy (e.g., IFL, FOLFOX)
- Non-squamous non-small cell lung cancer (NSCLC) - first-line, in combination with carboplatin and paclitaxel (unresectable, locally advanced, recurrent, or metastatic disease)
- Recurrent glioblastoma - as a single agent in adults with progressive disease following prior therapy
- Metastatic renal cell carcinoma - in combination with interferon alfa
- Persistent, recurrent, or metastatic cervical cancer - in combination with paclitaxel and cisplatin, or paclitaxel and topotecan
- Epithelial ovarian, fallopian tube, or primary peritoneal cancer - in combination with chemotherapy (front-line, platinum-resistant recurrent, or platinum-sensitive recurrent disease), per specific approved regimens
- Hepatocellular carcinoma - in combination with atezolizumab, in patients who have not received prior systemic therapy
Off-label ophthalmic use (distinct, compounded-preparation context)
Intravitreal (into-the-eye) Bevacizumab is widely used off-label around the world, including in Bangladesh, as a compounded/repackaged preparation for wet age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and neovascular glaucoma, because it is markedly less expensive than agents formally approved for intraocular use. This ophthalmic use is not FDA-approved and requires careful aseptic repackaging by a qualified compounding facility; it should only be given under the direct supervision of an ophthalmologist experienced in intravitreal injection.
Any use of Bevacizumab must be individualized and supervised by a qualified oncologist or ophthalmologist, as appropriate to the indication.
Dosage & Administration of Bevacizumab
Dosage of Bevacizumab is highly indication-specific and must always be prescribed and administered by a qualified oncologist (for systemic use) or ophthalmologist (for compounded intravitreal use). The table below summarizes commonly used regimens; actual dosing must follow the specific protocol chosen by the treating physician.
| Indication | Typical adult dose |
|---|---|
| Metastatic colorectal cancer | 5 mg/kg IV every 2 weeks (with bolus-IFL) or 10 mg/kg IV every 2 weeks (with FOLFOX4); second-line: 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks |
| Non-squamous NSCLC | 15 mg/kg IV every 3 weeks, with carboplatin and paclitaxel |
| Recurrent glioblastoma | 10 mg/kg IV every 2 weeks (single agent) |
| Metastatic renal cell carcinoma | 10 mg/kg IV every 2 weeks, with interferon alfa |
| Cervical cancer | 15 mg/kg IV every 3 weeks, with paclitaxel and cisplatin, or paclitaxel and topotecan |
| Ovarian/fallopian tube/peritoneal cancer | 10-15 mg/kg IV every 2-3 weeks depending on regimen and disease setting |
| Hepatocellular carcinoma | 15 mg/kg IV every 3 weeks, after atezolizumab, on the same day |
| Ophthalmic (off-label, compounded) | A micro-dose (typically ~1.25 mg in 0.05 mL) by intravitreal injection, administered only by an ophthalmologist; frequency per treatment protocol |
The first infusion is given over 90 minutes; if well tolerated, subsequent infusions may be shortened to 60 minutes, then 30 minutes, under close monitoring. Treatment should continue until disease progression or unacceptable toxicity, unless a fixed-duration regimen is specified.
Withhold Bevacizumab for at least 28 days before and after elective major surgery due to wound-healing risk (see Precautions and Warnings).
Side Effects of Bevacizumab
Bevacizumab carries serious, potentially fatal risks alongside common, generally manageable side effects. These differ substantially between systemic (intravenous, oncology) use and off-label ophthalmic (intravitreal) use.
Serious/boxed-warning-level risks (systemic use)
- Gastrointestinal perforation - can be fatal; presents as abdominal pain, fever, nausea, vomiting
- Severe or fatal hemorrhage - including pulmonary hemorrhage/hemoptysis, GI bleeding, CNS bleeding
- Surgical and wound-healing complications - including wound dehiscence
- Arterial and venous thromboembolic events (e.g., stroke, myocardial infarction, deep vein thrombosis, pulmonary embolism)
- Severe hypertension, hypertensive crisis, and posterior reversible encephalopathy syndrome (PRES)
- Nephrotic syndrome/severe proteinuria
- Congestive heart failure
- Ovarian failure (in premenopausal women)
Common side effects (systemic use)
Hypertension, proteinuria, fatigue/asthenia, diarrhea, abdominal pain, headache, decreased appetite, stomatitis, epistaxis (nosebleeds), altered taste, dry skin, rash, and low white blood cell counts.
Ophthalmic (intravitreal, off-label) use
Eye pain or irritation, transient increase in intraocular pressure, floaters, conjunctival hemorrhage, and rare but serious risks including endophthalmitis (intraocular infection), retinal detachment, and intraocular inflammation.
Report any severe abdominal pain, unusual bleeding, chest pain, sudden severe headache, vision changes, or signs of infection to a physician immediately.
Contraindications of Bevacizumab
Bevacizumab is contraindicated in patients with known severe hypersensitivity to Bevacizumab or to any component of the formulation, including hypersensitivity reactions to Chinese hamster ovary (CHO) cell products or other recombinant human or humanized antibodies.
No other absolute contraindications are established in the approved labeling; conditions such as recent surgery, active bleeding, uncontrolled hypertension, or pregnancy represent important precautions/relative contraindications requiring careful risk-benefit assessment rather than true absolute contraindications, and are discussed under Precautions and Warnings and Pregnancy and Lactation.
Frequently Asked Questions about Bevacizumab
What is Bevacizumab used for?
Bevacizumab is a targeted cancer medicine (an anti-VEGF monoclonal antibody) used in combination with chemotherapy or other agents to treat several cancers, including metastatic colorectal cancer, certain lung cancers, glioblastoma, kidney cancer, cervical cancer, ovarian cancer, and liver cancer. It is also used off-label, in a specially compounded low-dose form, by eye specialists to treat certain retinal diseases such as wet age-related macular degeneration.
How is Bevacizumab given?
For cancer treatment, Bevacizumab is given only as a slow intravenous infusion in a hospital or infusion center under close medical supervision, usually every 2 to 3 weeks, in combination with other cancer drugs. It is never injected at home or taken by mouth. Eye injections of Bevacizumab (an entirely separate, off-label use) are given only by an ophthalmologist in a clinical setting.
What are the most serious risks of Bevacizumab?
Bevacizumab carries serious risks including gastrointestinal perforation (a tear in the bowel wall, which can be fatal), severe or fatal bleeding, problems with wound healing after surgery, blood clots (including stroke and heart attack), severe high blood pressure, and kidney problems (proteinuria). Patients are closely monitored for these during treatment, and treatment may be stopped if they occur.
Can Bevacizumab be used during pregnancy or breastfeeding?
No. Bevacizumab may cause serious harm to a developing baby and is not recommended during pregnancy; women who can become pregnant should use effective contraception during and for at least 6 months after treatment. Breastfeeding is generally not recommended during treatment with Bevacizumab and for at least 6 months after the last dose, as it is not known whether it passes into breast milk. Always discuss this with your physician.
Does Bevacizumab interact with other medicines?
Yes. Combining Bevacizumab with sunitinib can cause a serious blood disorder and is generally avoided. Combining it with blood thinners (such as warfarin or aspirin) can increase bleeding risk. Bevacizumab is also deliberately combined with specific chemotherapy drugs as part of approved treatment regimens, which requires monitoring for added side effects. Always tell your doctor about all medicines you are taking.
Is Bevacizumab the same medicine used for eye injections that I may have heard about?
The active ingredient is the same, but for eye disease, Bevacizumab is used off-label in a very small, specially repackaged dose given directly into the eye by an ophthalmologist - this is a completely different product preparation, dose, and use from the intravenous cancer treatment, and is not FDA-approved for this purpose. It should only be given by a qualified eye specialist using proper sterile technique.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.